Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
Expert Rev Anticancer Ther. 2021 Oct 15. doi: 10.1080/14737140.2021.1993065. Online ahead of print.ABSTRACTIntroductionMetastatic triple-negative breast cancer (TNBC) is an aggressive cancer with poor survival that is difficult to treat due to a lack of targeted options. Conventional therapies targeting hormone receptors (HR) and human epidermal growth factor 2 (HER2) are ineffective and often chemotherapy is standard-of-care. Sacituzumab govitecan (IMMU-132) is an antibody drug conjugate (ADC) comprised of an active metabolite of irinotecan, SN-38, bound to a humanized monoclonal antibody which targets trophoblastic cell-...
Source: Expert Review of Anticancer Therapy - October 15, 2021 Category: Cancer & Oncology Authors: Anna R Schreiber Michelle Andress Jennifer R Diamond Source Type: research

Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19
Expert Rev Anticancer Ther. 2021 Oct 13. doi: 10.1080/14737140.2021.1991317. Online ahead of print.ABSTRACTIntroductionFor the clinical treatment of cancer patients, coronavirus (SARS-CoV-2) can cause serious immune-related problems. Cancer patients, who experience immunosuppression due to the pathogenesis and severity of disease, may become more aggressive due to multiple factors such as age, comorbidities, and immunosuppression. In this pandemic era, COVID-19 causes lymphopenia, cancer cell awakening, inflammatory diseases, and a cytokine storm that worsens disease-related morbidity and prognosis.Areas coveredWe discuss ...
Source: Expert Review of Anticancer Therapy - October 13, 2021 Category: Cancer & Oncology Authors: Anwar Ali Hafsa Mughal Nazir Ahmad Quratulain Babar Ayesha Saeed Waseem Khalid Hasnain Raza Aizhong Liu Source Type: research

Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy
Expert Rev Anticancer Ther. 2021 Oct 12. doi: 10.1080/14737140.2021.1991316. Online ahead of print.ABSTRACTINTRODUCTION: Doxorubicin (DOX) is a Streptomyces peucetius-derived antibiotic and is a member of the anthracyline family. DOX exerts strong anticancer activity and has been in the practice of cancer treatment since the 1960s. DOX is commonly used to treat different cancers, including bone sarcomas, soft tissue (tendons and muscles), bladder, ovary, stomach, thyroid, breast, acute lymphoblastic leukemia, Hodgkin lymphoma, lung cancer, and myeloblastic leukemia. Although, the cumulative doses of DOX above 550mg/m2 caus...
Source: Expert Review of Anticancer Therapy - October 12, 2021 Category: Cancer & Oncology Authors: Muhammad Sohail Zheng Sun Yanli Li Xuejing Gu Hui Xu Source Type: research

Repurposing antipsychotic drugs for cancer treatment: current evidence and future perspectives
Expert Rev Anticancer Ther. 2021 Oct 6. doi: 10.1080/14737140.2022.1987221. Online ahead of print.NO ABSTRACTPMID:34612130 | DOI:10.1080/14737140.2022.1987221 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - October 6, 2021 Category: Cancer & Oncology Authors: Georgios D Lianos George A Alexiou Stefano Rausei Vasiliki Galani Michail Mitsis Athanasios P Kyritsis Source Type: research

Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study
In this study, we compared Overall survival (OS) and lung cancer-specific survival (LCSS) after segmentectomy or lobectomy in stage IA1 (≤10 mm) lung adenocarcinoma (LUAD) patients.RESEARCH DESIGN AND METHODS: We retrospectively recruited patients who'd been diagnosed with lung cancer for the first time and treated with segmentectomy or lobectomy, with or without previous other malignancy.RESULTS: 1788 patients were included. After propensity score matching: 5-year OS were 85.6% for segmentectomy and 84.7% for lobectomy(p=0.951); 5-year LCSS were 93.5% for segmentectomy and 93.0% for lobectomy(p=0.726). Cox regression a...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Wenliang Bai Jiaqi Zhang Yanqing Wang Mengxin Zhou Lei Liu Guige Wang Ke Zhao Xuehan Gao Shanqing Li Source Type: research

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Expert Rev Anticancer Ther. 2021 Oct 1. doi: 10.1080/14737140.2021.1988853. Online ahead of print.ABSTRACTINTRODUCTION: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to add to the armamentarium. Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate (ADC), was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (DLBCL).AREAS COVERED: We review the design and pharmacologic characteristics...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Nausheen Ahmed Mehdi Hamadani Source Type: research

Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study
In this study, we compared Overall survival (OS) and lung cancer-specific survival (LCSS) after segmentectomy or lobectomy in stage IA1 (≤10 mm) lung adenocarcinoma (LUAD) patients.RESEARCH DESIGN AND METHODS: We retrospectively recruited patients who'd been diagnosed with lung cancer for the first time and treated with segmentectomy or lobectomy, with or without previous other malignancy.RESULTS: 1788 patients were included. After propensity score matching: 5-year OS were 85.6% for segmentectomy and 84.7% for lobectomy(p=0.951); 5-year LCSS were 93.5% for segmentectomy and 93.0% for lobectomy(p=0.726). Cox regression a...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Wenliang Bai Jiaqi Zhang Yanqing Wang Mengxin Zhou Lei Liu Guige Wang Ke Zhao Xuehan Gao Shanqing Li Source Type: research

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Expert Rev Anticancer Ther. 2021 Oct 1. doi: 10.1080/14737140.2021.1988853. Online ahead of print.ABSTRACTINTRODUCTION: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to add to the armamentarium. Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate (ADC), was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (DLBCL).AREAS COVERED: We review the design and pharmacologic characteristics...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Nausheen Ahmed Mehdi Hamadani Source Type: research

Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study
In this study, we compared Overall survival (OS) and lung cancer-specific survival (LCSS) after segmentectomy or lobectomy in stage IA1 (≤10 mm) lung adenocarcinoma (LUAD) patients.RESEARCH DESIGN AND METHODS: We retrospectively recruited patients who'd been diagnosed with lung cancer for the first time and treated with segmentectomy or lobectomy, with or without previous other malignancy.RESULTS: 1788 patients were included. After propensity score matching: 5-year OS were 85.6% for segmentectomy and 84.7% for lobectomy(p=0.951); 5-year LCSS were 93.5% for segmentectomy and 93.0% for lobectomy(p=0.726). Cox regression a...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Wenliang Bai Jiaqi Zhang Yanqing Wang Mengxin Zhou Lei Liu Guige Wang Ke Zhao Xuehan Gao Shanqing Li Source Type: research

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Expert Rev Anticancer Ther. 2021 Oct 1. doi: 10.1080/14737140.2021.1988853. Online ahead of print.ABSTRACTINTRODUCTION: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to add to the armamentarium. Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate (ADC), was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (DLBCL).AREAS COVERED: We review the design and pharmacologic characteristics...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Nausheen Ahmed Mehdi Hamadani Source Type: research

Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study
In this study, we compared Overall survival (OS) and lung cancer-specific survival (LCSS) after segmentectomy or lobectomy in stage IA1 (≤10 mm) lung adenocarcinoma (LUAD) patients.RESEARCH DESIGN AND METHODS: We retrospectively recruited patients who'd been diagnosed with lung cancer for the first time and treated with segmentectomy or lobectomy, with or without previous other malignancy.RESULTS: 1788 patients were included. After propensity score matching: 5-year OS were 85.6% for segmentectomy and 84.7% for lobectomy(p=0.951); 5-year LCSS were 93.5% for segmentectomy and 93.0% for lobectomy(p=0.726). Cox regression a...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Wenliang Bai Jiaqi Zhang Yanqing Wang Mengxin Zhou Lei Liu Guige Wang Ke Zhao Xuehan Gao Shanqing Li Source Type: research

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Expert Rev Anticancer Ther. 2021 Oct 1. doi: 10.1080/14737140.2021.1988853. Online ahead of print.ABSTRACTINTRODUCTION: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to add to the armamentarium. Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate (ADC), was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (DLBCL).AREAS COVERED: We review the design and pharmacologic characteristics...
Source: Expert Review of Anticancer Therapy - October 1, 2021 Category: Cancer & Oncology Authors: Nausheen Ahmed Mehdi Hamadani Source Type: research

Molecular-driven treatment for biliary tract cancer: the promising turning point
Expert Rev Anticancer Ther. 2021 Sep 24:1-12. doi: 10.1080/14737140.2021.1982699. Online ahead of print.ABSTRACTINTRODUCTION: In the past, targeted therapies have not shown positive results as they have been used without adequate molecular selection of patients with biliary tract cancer (BTC). This has led to an expansion of research on characteristics and molecular selection to identify new effective strategies in this setting. Improved knowledge of the molecular biology of these neoplasms has highlighted their extraordinary heterogeneity and has made it possible to identify targetable gene alterations, including fibrobla...
Source: Expert Review of Anticancer Therapy - September 23, 2021 Category: Cancer & Oncology Authors: Mara Persano Marco Puzzoni Pina Ziranu Valeria Pusceddu Eleonora Lai Andrea Pretta Clelia Donisi Giovanna Pinna Dario Spanu Erika Cimbro Alissa Parrino Nicole Liscia Stefano Mariani Marco Dubois Marco Migliari Mario Scartozzi Source Type: research

Molecular-driven treatment for biliary tract cancer: the promising turning point
Expert Rev Anticancer Ther. 2021 Sep 23. doi: 10.1080/14737140.2021.1982699. Online ahead of print.ABSTRACTINTRODUCTION: In the past, targeted therapies have not shown positive results as they have been used without adequate molecular selection of patients with biliary tract cancer (BTC). This has led to an expansion of research on characteristics and molecular selection to identify new effective strategies in this setting. Improved knowledge of the molecular biology of these neoplasms has highlighted their extraordinary heterogeneity and has made it possible to identify targetable gene alterations, including fibroblast gr...
Source: Expert Review of Anticancer Therapy - September 23, 2021 Category: Cancer & Oncology Authors: Mara Persano Marco Puzzoni Pina Ziranu Valeria Pusceddu Eleonora Lai Andrea Pretta Clelia Donisi Giovanna Pinna Dario Spanu Erika Cimbro Alissa Parrino Nicole Liscia Stefano Mariani Marco Dubois Marco Migliari Mario Scartozzi Source Type: research

Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
Expert Rev Anticancer Ther. 2021 Sep 20. doi: 10.1080/14737140.2021.1982698. Online ahead of print.ABSTRACTINTRODUCTION: Although various new drugs have been developed, the prognosis of therapeutic advances for metastatic gastric cancer is insufficient. Trastuzumab deruxtecan (T-DXd), a new human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate (ADC), has demonstrated promising results in clinical trials.AREAS COVERED: In this article, we review the history of anti-HER2 ADCs and focus on the efficacy and safety of T-DXd and describe the development of new anti-HER2 drugs.EXPERT OPINION: Until now...
Source: Expert Review of Anticancer Therapy - September 20, 2021 Category: Cancer & Oncology Authors: Takahiro Ishii Kohei Shitara Source Type: research

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?
Expert Rev Anticancer Ther. 2021 Sep 16. doi: 10.1080/14737140.2021.1982387. Online ahead of print.ABSTRACTINTRODUCTION: Surgical resection is the standard of care in non-small cell lung cancer (NSCLC) for early stage disease (stage I-IIIA). Despite the use of adjuvant chemotherapy, the 5- year overall survival (OS) rates remain low. In NSCLC with advanced stages (stage IV), tailored strategies have become the gold standard approach applying precision medicine thanks to the introduction of genomic analysis with next generation sequencing (NGS) and the development of targeted therapy and immunotherapy. We hope to translate ...
Source: Expert Review of Anticancer Therapy - September 16, 2021 Category: Cancer & Oncology Authors: Carolina Gabay Alessandro Russo Luis E Raez Christian Rolfo Cervetto Source Type: research

Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management
Expert Rev Anticancer Ther. 2021 Sep 13. doi: 10.1080/14737140.2021.1979396. Online ahead of print.ABSTRACTINTRODUCTION: Immune checkpoint inhibitors (ICIs) are a new class of anticancer drugs that enhance the immune system function and activate T cells against cancerous cells. Although cardiac complications are not common, they could be accompanied with high morbidity and mortality.AREAS COVERED: Regarding the importance of cardiac complications and their subsequent burden on individuals and the healthcare system, this review attempts to discuss the mechanism, diagnosis, and management of myocarditis, besides recapitulati...
Source: Expert Review of Anticancer Therapy - September 13, 2021 Category: Cancer & Oncology Authors: Seyed Parsa Eftekhar Niloufar Yazdanpanah Nima Rezaei Source Type: research

Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium
CONCLUSIONS: The 2021 ASCO Genitourinary Cancers Symposium significantly contributed to the complex research goal of intimately understanding PC carcinogenesis with the ultimate aim of improving patient outcomes.PMID:34493147 | DOI:10.1080/14737140.2021.1976148 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - September 8, 2021 Category: Cancer & Oncology Authors: Roberto Iacovelli Serena Astore Chiara Ciccarese Maria Antonella Cannella Pierluigi Bove Valerio Iacovelli Giampaolo Tortora Source Type: research

2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma
CONCLUSIONS: This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.PMID:34482771 | DOI:10.1080/14737140.2021.1976147 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - September 6, 2021 Category: Cancer & Oncology Authors: Roberto Iacovelli Maria Antonella Cannella Chiara Ciccarese Serena Astore Nazario Foschi Giuseppe Palermo Giampaolo Tortora Source Type: research

2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma
This article describes the main acquisitions of RCC management, including the advent of a new combo (pembrolizumab+lenvatinib) as first-line therapy, the confirmation of an OS advantage of ICI plus VEGFR-TKI combinations over sunitinib at longer follow-up, the persistent benefit from these combinations in particular subgroups (clear cell mRCC tumors with sarcomatoid differentiation), and possible new approaches in subsequent lines of therapy (including the HIF-2α inhibitor belzutifan). This 2021 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly pe...
Source: Expert Review of Anticancer Therapy - September 6, 2021 Category: Cancer & Oncology Authors: Roberto Iacovelli Maria Antonella Cannella Chiara Ciccarese Serena Astore Nazario Foschi Giuseppe Palermo Giampaolo Tortora Source Type: research

Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
We present an up-to-date evaluation of preclinical evidence for RTK inhibition with cabozantinib, specifically VEGFR, MET, KIT, RET, AXL, FLT3, and associated antitumor effects. Preclinical investigations of cabozantinib in combination with other anticancer drugs are also reviewed.EXPERT OPINION: Preclinical evidence shows that cabozantinib has antitumor activity against various cancer cells and exhibits synergy with other anticancer agents, including immune checkpoint inhibitors and hormone receptor or metabolic pathway inhibitors. Further optimization of cabozantinib treatment requires the identification of biomarkers of...
Source: Expert Review of Anticancer Therapy - August 27, 2021 Category: Cancer & Oncology Authors: Matteo Santoni Roberto Iacovelli Valentina Colonna Stephan Klinz Giorgio Mauri Marianna Nuti Source Type: research

Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
We present an up-to-date evaluation of preclinical evidence for RTK inhibition with cabozantinib, specifically VEGFR, MET, KIT, RET, AXL, FLT3, and associated antitumor effects. Preclinical investigations of cabozantinib in combination with other anticancer drugs are also reviewed.EXPERT OPINION: Preclinical evidence shows that cabozantinib has antitumor activity against various cancer cells and exhibits synergy with other anticancer agents, including immune checkpoint inhibitors and hormone receptor or metabolic pathway inhibitors. Further optimization of cabozantinib treatment requires the identification of biomarkers of...
Source: Expert Review of Anticancer Therapy - August 27, 2021 Category: Cancer & Oncology Authors: Matteo Santoni Roberto Iacovelli Valentina Colonna Stephan Klinz Giorgio Mauri Marianna Nuti Source Type: research

Radiomics, mirnomics and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light
Expert Rev Anticancer Ther. 2021 Aug 26. doi: 10.1080/14737140.2021.1971518. Online ahead of print.ABSTRACTINTRODUCTION: Glioblastoma is a highly aggressive brain tumor with an extremely poor prognosis. Genetic characterization of this tumor has identified alterations with prognostic and therapeutic impact, and many efforts are being made to improve molecular knowledge on glioblastoma. Invasive procedures, such as tumor biopsy or radical resection, are needed to characterize the tumor.AREAS COVERED: The role of microRNA in cancer is an expanding field of research as many microRNAs have been shown to correlate with patient ...
Source: Expert Review of Anticancer Therapy - August 26, 2021 Category: Cancer & Oncology Authors: Ilaria Maggio Enrico Franceschi Lidia Gatto Alicia Tosoni Vincenzo Di Nunno Caterina Tonon Alba A Brandes Source Type: research